Asia Mattelab
Distributes 3D bioprinters and scientific lab equipment for research and industrial laboratories, providing consultation and technical support.
- CEO / Founder
- Brice Oh
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- S$12.7M
- Latest Round
- Series A
- Key Investors
- Temasek Holdings, EDBI, Tessa Therapeutics, Plug and Play Ventures
Technology & Products
Key Products
3D bioprinters (e.g., r3bEL bioprinter) and scientific lab equipment for bioscience research and education.
Technological Advantage
Partnership with SE3D for r3bEL bioprinter distribution provides access to bioprinting technology without in-house R&D; focus on customer consultation and after-sales service builds trust in research community.
Differentiation
Value Proposition
Provides access to specialized 3D bioprinting technology (e.g., r3bEL bioprinter) and lab equipment with expert consultation, reducing procurement complexity and ensuring proper implementation for bioscience research and education.
How They Differentiate
As a distributor rather than manufacturer, focuses on customer consultation and support in Southeast Asia, unlike direct bioprinter makers like CELLINK or Allevi.
Market & Competition
Target Customers
Research laboratories, universities, pharmaceutical companies, biotechnology firms
Industry Verticals
Pharmaceuticals; Biotechnology; Medical Research; Education
Competitors
CELLINK, Allevi
Growth & Milestones
Growth Metrics
Reported annual revenue of $2.0 million in 2024
Major Milestones
Incorporated in 2013; Established distribution partnerships with multiple scientific equipment manufacturers; Listed in VoxelMatters directory as an AM industry participant
Notable Customers
A*STAR; Tessa Therapeutics; Pfizer Asia-Pacific; NUS Medicine